ALK阳性晚期NSCLC治疗进展       
NP-ALE-2017.10-004 Valid Until 2019.10
ALK阳性晚期NSCLC治疗进展       
ALK 阳性NSCLC治疗现状ALK 阳性NSCLC一线治疗的突破ALK 阳性患者整体治疗策略
2016ALK+可见于约5%左右的晚期NSCLC病人每年新确诊75,000以上例患者
ALK通路及药物发展简史
2011Crizotinib, the first ALK inhibitor, approved
2014 (Jul)Alectinib approved in Japan
2013 (Jun)FDA granted Alectinib BTD for ALK+ NSCLC patients who have progressed on crizotinib
2007Japanese researchers identified ALK oncogene in NSCLC patients
2015   (Dec)Alectinib FDA approval for ALK-positive NSCLC progressing o ...